CCL Products Ltd (Q4 FY16): Stupendous quarter led by strong volume growth!!! – BUY
|
||
Click here for the detailed report on the same. |
||
Shriram Transport Finance Ltd – Call Success In our Q3 FY16 update, we recommended a BUY on Shriram Transport Fin with a 12-month target price of Rs. 1028. The stock surpassed our target in yesterday’s trading session. Company’s operational performance in Q4 FY16 was better than expected on stand-alone basis and over the longer term it should improve significantly on the back of expected good monsoon and recovery in infra and industrial activity. |
||
Click here for the detailed report on the same. |
ICICI Bank Ltd. (Q4 FY16): Credit stress to stay – BUY
|
||
Click here for the detailed report on the same. |
||
Idea Cellular (Q4 FY16): Pricing drives a solid quarter – BUY
|
||
Click here for the detailed report on the same. |
||
Granules India (Q4 FY16): Robust operating performance – BUY
|
||
Click here for the detailed report on the same. |
||
Vedanta Ltd. (Q4 FY16): Valuations attractive – Accumulate
|
||
Click here for the detailed report on the same. |
Orient Cement Ltd (Q4 FY16): In-line with expectation – BUY
|
||
Click here for the detailed report on the same. |
Dear Sir
I hold 400 shares of CAPITAL FIRST at 485
Can hold fir 5 years when my retirement is due.i.e.in 2021
What should i do BUY SELL OR HOLD
pl guide
Granules India Ltd announced that it has posted a 48 per cent growth in its consolidated net profit at Rs. 33 crore in the fourth quarter ended March 31, 2016 as against Rs. 22 crore in the fourth quarter ended March 31, 2015.
The total revenues of the company rose by 5 per cent to Rs. 373 crore during the period under review as compared to Rs. 355 crore during the same period a year ago.
Commenting on this, Krishna Prasad Chigurupati, Chairman & Managing Director, Granules India Ltd said that they witnessed a gentle top line growth. However, the bottom line outshined with good margins in turn validating their superiority in operational competence.
Moreover, the consolidated net profit of the Hyderabad-based company surged by 30 per cent to Rs. 118 crore for the full year 2015-16 as against Rs 91 crore for the full year 2014-15 on revenue of Rs. 1,431 crore, up by 11 per cent against Rs. 1,294 crore in the last financial year.
Meanwhile, the board of directors of the firm proposed a final dividend of 20 paise/share of face value of Rs. 1 each.
The company saw the commercialization of its CRAMS business, ANDA approval for Ibuprofen Rx as well as the construction of a new capacity. It was witnessed expansion of R&D initiatives during the year under review.
Prasad added that this year as well as the next year , they are hoping to build a robust and agile company that will surface as a well-organized pharmaceutical manufacturing partner with major emphasis on research and development.
Earlier today, the company said that its board has approved investment of about Rs 167 crore in various arms.
Granules share price was trading at Rs 135.85 apiece, up 2.03 per cent, from previous close on National Stock Exchange (NSE) at 12.10 hours.
Dynamiclevels recommends Granules India Ltd as one of our Multibagger Stocks.
To see more https://www.dynamiclevels.com/en/granules-share-price-forecast
#Multibaggerstockideas::
CCL products is a company which operates in Beverages segment. It is engaged in manufacture of coffee powder, liquid coffee, dried coffee and other related products. The company has strong fundamentals with ROE of more than 23% and ROCE of more than 30%. The company has posted CAGR of 20-21% in revenue and 35-40% CAGR in net profit over the last 3-4 years. In FY 17, also the company expects to grow its bottom line by 25%. It is available at PE of 25 at the moment. So on any declines the stock can be added with a target of 280-300 in next 1-1.5 years.
Visit for more stock tips @ Multibagger Stock Ideas